(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 3.64% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.22%.
Gilead Sciences's revenue in 2025 is $28,863,000,000.On average, 30 Wall Street analysts forecast GILD's revenue for 2025 to be $36,767,590,534,912, with the lowest GILD revenue forecast at $34,774,854,627,816, and the highest GILD revenue forecast at $38,718,139,006,864.  On average, 30 Wall Street analysts forecast GILD's revenue for 2026 to be $37,978,618,084,928, with the lowest GILD revenue forecast at $34,927,473,878,484, and the highest GILD revenue forecast at $40,713,356,527,792.  
In 2027, GILD is forecast to generate $40,044,561,600,068 in revenue, with the lowest revenue forecast at $37,277,562,177,388 and the highest revenue forecast at $42,404,576,354,300.